GCM
LXRX icon

Graham Capital Management’s Lexicon Pharmaceuticals LXRX Stock Holding History

Graham Capital Management’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$53.1K Sell
34,027
-75,873
-69% -$110K ﹤0.01% 1089
2025
Q4 		$126K Buy
+109,900
New +$151K ﹤0.01% 1123

Other funds holding LXRX

AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
SC
Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Graham Capital Management's LXRX Position: Q1 2026 in Review

Graham Capital Management reduced its Lexicon Pharmaceuticals (LXRX) stake by 69% in Q1 2026, selling an estimated $110K and leaving 34,027 shares worth $53.1K. The position accounts for ﹤0.01% of the portfolio, ranked #1089.

Graham Capital Management first reported a position in LXRX in Q4 2025 and has held it in 2 quarters since. The position peaked at $126K in Q4 2025. 136 funds tracked by Wall St. Rank hold LXRX as of Q1 2026.

  • Graham Capital Management held 34,027 shares of Lexicon Pharmaceuticals worth $53.1K as of Q1 2026.
  • Graham Capital Management sold 75,873 Lexicon Pharmaceuticals shares in Q1 2026, an estimated $110K.
  • Lexicon Pharmaceuticals made up ﹤0.01% of Graham Capital Management's portfolio in Q1 2026, its #1089 holding.
  • Graham Capital Management first reported a position in Lexicon Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • Graham Capital Management's Lexicon Pharmaceuticals position peaked at $126K in Q4 2025.
  • 136 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q1 2026.

Based on Graham Capital Management's 13F filing for Q1 2026, filed 15 May 2026.